Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Arista Networks Inc (ANET) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Arista Networks Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Arista Networks Inc trades at $176.5 (market cap $209.60B). The key difference: Arista Networks Inc is far larger — about 46.7× ACADIA Pharmaceuticals Inc.'s market cap, and Arista Networks Inc is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | ANET | |
|---|---|---|
Market Cap | $4.49B | $209.60B |
Sector | Health | Technology |
52-Week High | $28.06 | $177.73 |
52-Week Low | $20.06 | $103.39 |
Enterprise Value | $3.69B | $197.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Arista Networks (ANET) trades at $166.46, up 4.04% in the last session, with a bullish technical outlook and strong fundamental performance. The company reported revenue of $9.01B in 2025, with net income of $3.51B and a net margin of 38.32%. Recent quarters show consistent earnings beats, and analyst consensus is strongly bullish with a $192.82 price target. Technical indicators suggest the stock is near key resistance at $171, with support at $164.
ANET presents a compelling growth opportunity driven by AI networking demand and robust financials, but elevated valuation ratios (P/E 59.55) and competitive pressures pose risks. The stock's upside is supported by analyst optimism and institutional interest, though investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Arista Networks Inc
Arista Networks is a software and hardware provider for the networking solutions sector. Operating as one business unit, software, switching, and router products are targeted for high-performance networking applications, while service revenue comes from technical support. Customer markets include data centers, enterprises, service providers, and campuses. The company is headquartered in Santa Clara, California, and generates most of its revenue in the Americas.
Read more on ANET →
